Aetna is set to sell its drug plan business to WellCare Health Plans

By Catherine Sturman
US health insurance giant Aetna has announced its plans to sell its Medicare Part D drug plan business to WellCare Health Plans for an undisclosed sum...

US health insurance giant Aetna has announced its plans to sell its Medicare Part D drug plan business to WellCare Health Plans for an undisclosed sum.

The deal forms part Aetna’s wider strategic plans to secure approval for its $69bn merger with CVS Health, which was officially announced late last year. It also follows on from Cigna’s $52bn acquisition of Pharmacy Benefit Manager (PBM) Express Scripts, which has recently been approved by federal officials, providing advantages to consumers in both insurance and PBM markets.

"We are concerned with the considerable amount of debt — over $40bn — that CVS is taking on to finance this transaction," Maria Vullo, superintendent of New York State's Department of Financial Services stated.

See also

"The considerable pressure to repay debt would cause the resulting company to repay its substantial obligation before investing in pro-market and pro-consumer measures."

This new acquisition will become WellCare’s third acquisition in two years. The move will eliminate any potential obstacles against the deal, particularly from the Department of Justice. If successful, the deal will close in the fourth quarter.

A key player in the Medicaid insurance business, the company presently serves close to three million US citizens, but will aim to scale up its activities following the merger.

 

Share

Featured Articles

Comarch Diagnostic Point Boost for European Health Insurance

Healthtech specialist Comarch introduces Diagnostic Point, designed to improve health insurance across European markets

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Procurement & Supply Chain

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma